Studies on biomarkers for oxidative stress in patients with chronic myeloid leukemia

BACKGROUND: Chronic myeloid leukemia (CML) is a myeloproliferative disorder with a unique genetic rearrangement, the Philadelphia chromosome. High reactive oxygen species (ROS) levels favor oxidative stress, which could play a vital role in normal processes and various pathophysiologies including ne...

Full description

Bibliographic Details
Main Authors: Raj K. Singh, Anil K. Tripathi, Payal Tripathi, Sushma Singh, Ranjana Singh, Rizwan Ahmad
Format: Article
Language:English
Published: Elsevier 2009-01-01
Series:Hematology/Oncology and Stem Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S1658387609500398
Description
Summary:BACKGROUND: Chronic myeloid leukemia (CML) is a myeloproliferative disorder with a unique genetic rearrangement, the Philadelphia chromosome. High reactive oxygen species (ROS) levels favor oxidative stress, which could play a vital role in normal processes and various pathophysiologies including neoplasm. Biomarkers of oxidative stress are measured as products of oxidized proteins and lipids. Plasma levels of protein carbonyl (PC), thiobarbituric acid reactive substances (TBARS) and total lipid hydroperoxide (LOOH) were used as biomarkers of oxidative stress in the past. The aim of this study was to evaluate the products of protein oxidation and lipid peroxidation in plasma as biomarkers of oxidative stress in CML patients. PATIENTS AND METHODS: The study included 40 CML patients and 20 age- and sex-matched healthy volunteers. Of 40 CML patients, 28 were in chronic phase (CML-CP) and 12 in accelerated phase (CML-AP). Plasma levels of PC, TBARS and LOOH as biomarkers of oxidative stress were evaluated by spectrophotometric methods. RESULTS: There were significant differences (P<.05) in plasma levels of PC, TBARS and LOOH in CML, CML-CP and CML-AP patients as compared to controls. CONCLUSION: PC, TBARS and LOOH might reflect oxidative stress in CML patients and might be used as biomarkers in such patients.
ISSN:1658-3876